The combination of ferroptosis with immune checkpoint inhibition (PD-L1 downregulation) and activation of key immune cells, such as DCs, NK cells, and CD8+ T cells, provides a strong basis for further exploration of this system in cancer immunotherapy. This evidence concerns the gene CD8A and cancer.